Table 1.
The TRIM31 targets or interacting proteins.
| Target or interacting proteins | Modification | Effect | Outcome | Reference |
|---|---|---|---|---|
| P53 | K48-linked poly-ubiquitination | Degradation of p53 | Promoting the anoikis-resistance | (24) |
| TSC1/TSC2 | K48-linked poly-ubiquitination | Degradation of TSC1/TSC2 | Promoting HCC progression | (19) |
| TRAF2 | K63-linked poly-ubiquitination | Activation of NF-κB | Promoting the gemcitabine resistance | (28) |
| P53 | K63-linked poly-ubiquitination | Activation of p53 | Suppressing the proliferation and migration of breast cancer cell |
(22) |
| MAVS | K63-linked poly-ubiquitination | Promoting the formation of prion-like aggregates | Activation of antiviral immunity | (20) |
| USP18 | No | Promoting the K63-linked polyubiquitination of MAVS | Activation of antiviral immunity | (58) |
| HBx | K48-linked poly-ubiquitination | Degradation of HBx | Inhibiting HBV Replication | (62) |
| NLRP3 | K48-linked poly-ubiquitination | Degradation of NLRP3 | Attenuating NLRP3 inflammasome activation |
(70) |
| SYK | K27-linked poly-ubiquitination | Activation of SYK | Promoting antifungal immunity | (74) |